Two ASU professors receive 2018 NIH New Innovator Award

October 2, 2018

No. 1 in innovation” is an accolade Arizona State University proclaims proudly in all realms of university life. Today, ASU proved once again that it is deserving of such a title.     

ASU Professors Nicholas Stephanopoulos, assistant professor in the School of Molecular Sciences, and Rizal Hariadi, assistant professor in the Department of Physics, both researchers in the Biodesign Center for Molecular Design and Biomimetics, were announced as recipients of the 2018 NIH New Innovator Award. Nicholas Stephanopoulos, left, and Rizal Hariadi, right, are 2018 NIH New Innovator Award recipients and investigators at the Biodesign Center for Molecular Design and Biomimetics. Alex Green, center, won the honor in 2017. Photo by Deanna Dent/ASU Now Download Full Image

The award belongs to the NIH Common Fund’s High-Risk, High-Reward research program — a platform aimed at recognizing exceptional scientists with strategies that tackle biomedical conundrums.

The New Innovator Award specifically “supports exceptionally creative early career investigators who propose innovative, high-impact projects,” targeting investigators within 10 years of completing their doctoral degree or postdoctoral training. Stephanopoulos and Hariadi's awards are among the 58 given to investigators nationwide this year; each recipient receives a $2.3 million grant for a five-year project.

“This program supports exceptionally innovative researchers who have the potential to transform the biomedical field,” NIH Director Francis S. Collins said. “I am confident this new cohort will revolutionize our approaches to biomedical research through their groundbreaking work.”

Hao Yan, the center’s director since 2013 and a Milton D. Glick Distinguished Professor in Chemistry and Biochemistry, was integral in the hiring of each of these recipients. He believes that this award is “one of the most prestigious young faculty awards in this country.”

These aren't ASU’s first New Innovator recipients. In 2017, Alex Green, also a researcher at the Center for Molecular Design and Biomimetics, received the award for his project aimed at expanding on RNA nanotechnology research.

“We are really proud that three of the four recipients (at ASU) are in Biodesign and at this center. It’s a huge honor,” Yan added.  

According to Stephanopoulos, the award is NIH’s way of demonstrating support for ideas that might be considered “totally new and kind of crazy. The NIH is saying, 'We’re going to take a gamble on you to pioneer in this new area.'"

man standing in lab

Nicholas Stephanopoulos, a recipient of the 2018 New Innovator Award, is an assistant professor in the School of Molecular Sciences and an investigator in the Biodesign Center for Molecular Design and Biomimetics. Photo by Deanna Dent/ASU Now

Stephanopoulos’s lab focuses on peptide DNA nanotechnology, utilizing chemical techniques to build new hybrid nanomaterials while maintaining the programmability and structural control of the proteins.

The specific project he proposed to the NIH focused on increasing the lengths of synthetic proteins that can be made for applications in biomedicine.

“Basically, when you make proteins now, you have to make them in cells, which can be difficult for some proteins, and then you’re stuck with the natural amino acids," he said. "People have been trying to make proteins from synthetic peptides, and there is a reaction called native chemical ligation that links these peptides together. The problem is that only works up to a certain length.

“What I proposed was to make these peptides with two DNA handles on the ends. Each peptide ligation could be enhanced with DNA bringing those peptides together, carrying out the reaction, and then removing those DNA handles. You still have a DNA handle at the growing end of the protein, so you can link two peptides, chop off the DNA, and do this over and over again. In theory, you can get much longer proteins this way,” Stephanopoulos said.

Hypothetically, this technique could be used to synthesize membrane proteins, such as G-protein coupled receptors, which are integral to the initiation of signaling pathways in a cell and have been particularly challenging to study in detail.

“One of the big applications would be making completely synthetic proteins from synthetic amino acids. You can stabilize them, make better catalysts, integrate them into materials. Specifically, for this project, I proposed making membrane proteins called GPCRs, which are hard to make in cells and are very important in a number of biological areas. If you can make them synthetically, you can carry out modifications that enable structural biology on them,” Stephanopoulos said. 

Stephanopoulos completed his undergraduate degree at Harvard University and attended University of California, Berkeley for his PhD in chemistry. He originally intended to complete his MD–PhD, but later changed his tune when he realized that he preferred research. While in graduate school, he developed a keen interest in merging DNA nanotechnology with protein design, so he contacted Paul Rothemund, the inventor of DNA origami, who referred him to Yan. About five years after his first collaboration with Yan on a project, he was offered a position at the Biodesign Institute and has since been there for three years.  

To Stephanopoulos, this award is not only a payoff for hard work and innovative ideas, but it also represents an important component to science: fun.  

“This is one of the fun reasons to do science, to come up with these crazy ideas that push the envelope.”

Neal Woodbury, the director and professor for the School of Molecular Sciences, believes the relevance of Stephanopoulos’s research makes him worthy of such an award.

“The High-Risk, High-Reward NIH funding to Professor Stephanopoulos provides well-deserved recognition for his work on functional molecular design,” Woodbury said. “He is a rising young star in the field, and this work focuses on designing and producing a class of cell receptor that controls many of the key processes in biology, opening the door for the design of more effective drugs.”

man's portrait

Rizal Hariadi, a recipient of the 2018 New Innovator Award, is an assistant professor in the Department of Physics and an investigator for the Biodesign Center for Molecular Design and Biomimetics. Photo by Deanna Dent/ASU Now

Rizal Hariadi’s lab focuses on biomolecular interactions under different mechanical forces and uses techniques involving mathematics, protein engineering, single-molecule biophysics and DNA nanotechnology.

His proposal for the NIH addresses the functionality of a biomolecular system when force is applied, specifically in the context of malaria parasite invasion.

“Malaria, as we know, claims half a million lives every year. It is equivalent to one malaria death every minute, and it affects half of the world population. The cost is $12 billion in terms of economic burden, so it’s a big problem,” Hariadi said.

What’s unique about Hariadi’s approach is that he is using “DNA as a biophysical tool, not an information carrier.” DNA origami will be used to arrange the proteins associated with this host invasion and apply tension. By studying the biomechanical forces and their effect on the system, molecules can eventually be screened for their ability to disrupt the malaria parasite invasion, thus translating into drug screening methods to treat malaria.

“It is high risk because the jump from building DNA nanostructures to adding proteins to the structures is actually not a challenge that many labs would like to pursue,” Hariadi added.

Hariadi initially garnered an interest for science while participating on the Indonesian Physics Olympiad Team. After establishing his love for science, he went on to complete his undergraduate degree at Washington State University. His plan was to pursue genetics, but because he missed the math and level of rigor of physics, he decided to shift his focus to physics and biochemistry. At Caltech, where he completed his PhD, he worked with DNA nanotechnology. He went on to complete his postdoc at the University of Michigan and Harvard Medical School, where he studied actin and myosin interactions and super-resolution microscopy.

Hariadi knew that he wanted to work at a university that emphasized an interdisciplinary approach, so he found an NSF publication that listed such highly interdisciplinary institutes. Because the Biodesign Institute and ASU were on the list, he applied and was accepted as an investigator and has been researching there for two years.

To receive such an award as a young researcher is validation both for the university and the researcher.

“This is definitely the highlight of my career — I feel very honored I will get the support to pursue a big problem with a non-traditional approach. It is good to know that NIH acknowledged that ASU is a good, up-and-coming research university, which will help in attracting more talent to ASU,” Hariadi added.

Hariadi also noted that this recognition provides exposure to one of ASU’s biggest goals as a university: inclusion.

“ASU is truly an amazing place. At ASU right now, I am writing a paper with a father of five. I come across first-generation immigrants and students who are the first in their family to go to college. The fact that we are so open and inclusive — it doesn’t mean we cannot do elite research. These awards show that NIH acknowledges our strength in research,” Hariadi said. 

Yan believes that these awards are a testament to ASU’s research vision, one that’s characterized by an interdisciplinary focus.

“ASU has become a very notable, highly-recognized research university, working on interdisciplinary research, solving problems that will be useful for society. Because we have this concept of interdisciplinary research, over the last 10 years we have been able to recruit talents like Rizal, Nick and Alex — we have provided the environment to nurture them,” Yan said.

Gabrielle Hirneise

Assistant science writer , Biodesign Institute


First experiments at Europe's new X-ray laser reveal structure of antibiotic-disabling enzyme

International collaboration obtains the first scientific results from European XFEL

October 2, 2018

An international collaboration led by the Deutsches Elektronen-Synchrotron, or DESY, with participation from Arizona State University’s Biodesign Center for Applied Structural Discovery, the Department of Physics and the School of Molecular Sciences, has announced the results of the first scientific experiments at Europe's new X-ray free-electron laser, the European XFEL.

Over 120 international researchers collaborated on the study, whose findings — including the first new protein structure solved at the European XFEL — are reported in the advanced online edition of the journal Nature Communications. False-coloured scanning electron microscope image of two Klebsiella pneumoniae bacteria (yellow) interacting with a human white blood cell (green). Klebsiella pneumoniae, a bacterial enzyme that plays an important role in antibiotic resistance was examined by the new European XFEL instrument. (Klebsiella measures 1 to 2 microns long.) Credit: National Institute of Allergy and Infectious Diseases Download Full Image

Petra Fromme, director of the Biodesign Center for Applied Structural Discovery, underlined the significance of the first research study carried out using the new European XFEL: “One of the most exciting capabilities of X-ray lasers is being able to make movies of life’s most important processes at the atomic level. Our pioneering experiments at the European XFEL proved that you can resolve images that are only a millionth of a second apart."

The pioneering work not only demonstrated that the new research facility can speed up experiments by an order of magnitude, it also revealed a previously unknown structure of an enzyme responsible for antibiotic resistance.

“The groundbreaking work of the first team to use the European XFEL has paved the way for all users of the facility who greatly benefit from these pioneering experiments,” said European XFEL managing director Robert Feidenhans'l. “We are very pleased — these results show that the facility works even better than we had expected and is ready to deliver new scientific breakthroughs.”

“Being at a totally new class of facility, we had to master many challenges that nobody had tackled before,” said DESY scientist Anton Barty from the Center for Free-Electron Laser Science (CFEL), who led the team of about 125 researchers involved in the first experiments that were open to the whole scientific community. “I compare it to the maiden flight of a novel aircraft: All calculations and assembly completed, everything says it will work, but not until you try it do you know whether it actually flies.”

The mechanics of discovery

The European XFEL is designed to deliver X-ray flashes every 220 nanoseconds (0.000 000 220 seconds). To unravel the three-dimensional structure of a biomolecule, such as an enzyme, the pulses are used to obtain flash X-ray exposures of tiny crystals of that biomolecule. Each exposure gives rise to a characteristic diffraction pattern on the detector. If enough such patterns are recorded from all orientations of a crystal, the atomic structure of the biomolecule can be calculated. However, every crystal can only be X-rayed once since it is vaporized by the intense flash (after it produced a diffraction pattern). So, to build up the full three-dimensional structure of the biomolecule, a new crystal has to be delivered into the beam in time for the next flash, by spraying it across the path of the laser in a water jet.

Nobody has tried to image molecules with X-rays at atomic resolution at this lightning pace before. The fastest pulse rate so far of any such X-ray laser has been 120 flashes per second, that is one flash every 0.0083 seconds (or 8, 333, 333 nanoseconds). To probe biomolecules at full speed, the water jet carrying the tiny crystals (which are also vaporized by the X-rays), must recover in time to be able to replenish the crystals fast enough.

“We revved up the speed of the water jet carrying the samples to 220 miles per hour, that's about as fast as the speed record in Formula 1,” explained Max Wiedorn, who led the sample delivery together with his colleague Dominik Oberthür, both from CFEL. A specially designed nozzle, whose development was led by Saša Bajt, a group leader at DESY, was critical to ensuring the high-speed jet would be stable and meet the requirements.

To record X-ray diffraction patterns at this fast rate, an international consortium led by DESY scientist Heinz Graafsma designed and built one of the world's fastest X-ray cameras, tailor-made for the European XFEL. The Adaptive Gain Integrating Pixel Detector (AGIPD) can not only record images as fast as the X-ray pulses arrive, it also automatically tunes the sensitivity of every pixel individually, providing much more accurate measurements of the diffraction patterns in which the information on the atomic structure of the sample is encoded.

“The requirements of the European XFEL are so unique that the detector had to be designed completely from scratch and tailored to this task,” reported Graafsma, who heads the detector group at DESY's Photon Science division and is also a professor at the Mid Sweden University. “This could only be achieved thanks to the comprehensive expertise and fruitful collaboration of the large team involved.”

Principles of crystallography: The electron beam (blue) passes through a magnetic slalom course, called an undulator, where the electrons send out X-ray light that adds up to short laser-like pulses. The X-rays produce a characteristic diffraction pattern when they hit a crystal of the sample. The pattern is recorded by a detector and analyzed with computers to reveal the spatial structure of the crystal's building blocks, which are the biomolecules under investigation.

"It was exciting and somewhat nostalgic to see the first protein diffraction patterns at the European XFEL appearing live, reminiscent of the first atomic-resolution SFX patterns we saw live at LCLS over 7 years ago, which marked the beginning of the high-resolution SFX era. Many of the same collaborators were involved in both historic experiments," said co-author Nadia Zatsepin, research assistant professor in the Department of Physics at ASU who leads SFX data analysis in the NSF BioXFEL Science and Technology Center.

"The ability to collect data much faster means we can determine many more frames of molecular movies with dramatically reduced amount of the precious samples, which can be critical for structure determination for many important biological samples, especially for studying dynamics. However, carrying out these very first experiments as part of commissioning the XFEL source and novel detector involved overcoming some unique challenges. The excellent results in this publication, and indeed the facilitating of SFX experiments following these pioneering efforts, is testament to the effective leadership and organization and sincere camaraderie of this large collaboration."

Some of the researchers involved in the new study: From left, Henry Chapman (CFEL), Anton Barty (CFEL), Adrian Mancuso (XFEL), Keith Nugent (La Trobe University ), Susannah Holmes (La Trobe University), Brian Abbey (La Trobe University), Connie Darmanin (La Trobe University), Andrew Morgan (CFEL) and Nadia Zatsepin (ASU).

The scientists first determined the structure of a very well-known sample, the enzyme lysozyme from egg white, as a touchstone to verify the system worked as expected. Indeed, the structure derived at the European XFEL perfectly matches the known lysozyme structure, showing details as fine as 0.18 nanometers (millionths of a millimeter).

“This is an excellent proof of the X-ray laser's performance,” said XFEL pioneer Henry Chapman, a leading scientist at DESY, division director of CFEL, and a professor at the University of Hamburg. “We are very excited about the speed of the analysis: Experiments that used to take hours can now be done in a few minutes, as we have shown. And the set-up that we used can even be further optimized, speeding up data acquisition even more. The European XFEL offers bright prospects for the exploration of the nanocosm.”

The striking performance of the X-ray laser is also a particular success for the DESY Accelerator Division that operates the European XFEL and led the construction of the world's longest and most advanced superconducting linear accelerator, which drives the European XFEL.

Exploring a new frontier

As their second target, the team chose a bacterial enzyme that plays an important role in antibiotic resistance. The molecule, designated CTX-M-14 β-lactamase, was isolated from the bacterium Klebsiella pneumoniae whose multidrug-resistant strains are a grave concern in hospitals worldwide. Two years ago, a "pandrug-resistant" strain of Klebsiella pneumoniae — unaffected by all 26 commonly available antibiotics — was identified in the U.S., according to the Centers for Disease Control and Prevention.

The bacterium's enzyme CTX-M-14 β-lactamase, is present in all strains. It works like a molecular pair of scissors, cutting open the lactam rings of penicillin-derived antibiotics open, thereby rendering them useless. To avoid this, antibiotics are often administered together with a compound called avibactam that blocks the molecular scissors of the enzyme. Unfortunately, mutations change the form of the scissors. “Some hospital strains of Klebsiella pneumoniae are already able to cleave even specifically developed third generation antibiotics,” explained Christian Betzel, co-author of the paper and also a professor at the University of Hamburg. “If we understand how this happens, it might help to design antibiotics that avoid this problem.”

The scientists investigated a complex of CTX-M-14 β-lactamase from the nonresistant, "wild type" of the bacterium with avibactam bound to the enzyme's active center, a structure that has not been analyzed before. “The results show with 0.17 nanometer precision, how avibactam fits snug into a sort of canyon on the enzyme's surface that marks its active center,” said Markus Perbandt from the University of Hamburg, also a co-author of the paper. “This specific complex has never been seen before, although the structure of the two separate components were already known.”

These successful measurements show that it is possible to record high-quality structural information, which is the first step towards recording time-resolved snapshots of the biochemical reaction between enzymes and their substrates at different stages, using the European XFEL. Together with the research group of co-authors Martin Aepfelbacher and Holger Rohde, professors at the University Hospital UKE in Hamburg, the team plans to use the X-ray laser as a film camera to assemble those snapshots into movies of the molecular dynamics of avibactam and this β-lactamase. “Such movies would give us crucial insights into the biochemical process that could one day help us to design better inhibitors, reducing antibiotic resistance,” said Betzel.

Just the beginning for XFEL

Movies of chemical and biochemical reactions are just one example of a whole new spectrum of scientific experiments possible at the European XFEL. The truly breakthrough feature is the rate at which data can be collected. “This opens up new avenues of structural discovery,“ said European XFEL scientist Adrian Mancuso, who heads the SPB/SFX instrument (Single Particles, Clusters and Biomolecules & Serial Femtosecond Crystallography) where the pioneering experiments were done. “The difference in rate of discovery possible using European XFEL demonstrated by this experiment is as dramatic as the difference in travel time between being able to catch a plane across the Atlantic rather than taking a ship. The impact is potentially enormous.”

This first "beamtime" for experiments at the European XFEL took place two weeks after the opening of the facility in September 2017, and was open to all scientists from the community to participate, contribute, learn and gain experience in how to carry out such measurements at this facility. “The success of this ‘open science’ policy is illustrated by — among other things — the rapid dissemination of results from later campaigns at the SPB/SFX instrument by participating groups,” explained Chapman. “Additionally, the large concentration of effort by the community addressed previously unsolved challenges of managing and visualizing data — crucial to conducting all serial crystallography experiments at the European XFEL.”

“This work at the European XFEL is very important for the study of biological processes, as it will enable the study of biological reactions in real time," said John Spence, professor at the Department of Physics at ASU. "As the scientific director of the BioXFEL Science and Technology Center, which is supported by the National Science Foundation, I am very excited that members of the BioXFEL STC have made major contributions to this exciting first user experiment at the European XFEL."

Richard Harth

Science writer, Biodesign Institute at ASU